Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment

Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis

“…In patients with CHC it is extremely important to ensure complete adherence to therapy with peg-IFN and RBV in order to achieve therapeutic success (greater percentage of SVR). Indeed, early interruption of therapy or reduction of peg-IFN or RBV dose because of side effects, leads to a significant decrease in SVR [21,[41][42][43].…”

“…However, several factors contribute to imperfect adherence to therapy or, in some cases, to its interruption: therapy-induced reduction in haemoglobin levels is the most important cause of drop out during treatment with peg-IFN and RBV [13][14][15][16][17][18][19][20]. As a result of this, RBV dose reduction is required, with a corresponding decrease in the chance of an SVR [21].…”

Community‐based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use

“…3 Such treatment leads to a sustained virological response in over 50% of those who comply with the 24-to 48-week course. Poor compliance leads to reduced response rates [3][4][5][6] and, as therapy is associated with many side effects, 7 considerable patient motivation is required to maximize the treatment benefits. Therapy is expensive, although cost-effective in the medium term.…”

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin

“…Moreover, reducing RBV dose prior to achieve HCV RNA below the LLOQ had no negative impact on achieving SVR12. Previous studies evaluating pegIFN/RBV therapy also concluded that mild to moderate RBV dose reductions do not adversely affect SVR rates 18, 19…”